Does Tigecycline Raise Liver Enzymes During Extended Use?
Yes, extended tigecycline therapy can lead to higher liver enzyme levels. Tigecycline, a glycylcycline antibiotic used for complicated infections, carries warnings for hepatotoxicity, with elevated transaminases (ALT/AST) reported in clinical trials and post-marketing data. In phase 3 trials, 2-3% of patients on tigecycline had ALT elevations >8x upper limit of normal (ULN), rising with longer durations beyond 14 days.[1][2]
How Common Is This in Long-Term Therapy?
Incidence increases with treatment length. Short courses (7-14 days) show mild, reversible ALT/AST rises in 1-5% of patients. Extended therapy (>14 days), often for multidrug-resistant infections, reports rates up to 10-15% for significant elevations, per real-world studies and FDA labeling. A retrospective analysis of 100+ patients on prolonged tigecycline found 12% developed ALT >5x ULN, mostly after 21 days.[3][4]
What Causes Tigecycline-Induced Liver Changes?
Tigecycline inhibits mitochondrial protein synthesis, disrupting hepatocyte function and leading to cholestasis or hepatocellular injury. Risk factors include pre-existing liver disease, higher doses (100mg loading then 50mg BID), and combinations with other hepatotoxins like vancomycin. Elevations are typically asymptomatic and peak 1-2 weeks into therapy.[1][5]
How Long Do Elevations Last and When to Monitor?
Levels often normalize 1-4 weeks post-discontinuation, but rare cases progress to severe injury (e.g., Hy's law criteria). Guidelines recommend baseline LFTs, monitoring every 3-7 days during extended use, and stopping if ALT >5x ULN with symptoms or bilirubin rise.[2][4] No specific antidote exists; supportive care applies.
Are There Safer Alternatives for Long-Term Use?
For extended therapy in resistant infections, alternatives like eravacycline or omadacycline show lower hepatotoxicity (ALT elevations <2% in trials). Colistin or newer beta-lactams may suit specific pathogens but carry renal risks. Switch if LFTs climb early.[6]
[1] FDA Label: Tygacil (tigecycline)
[2] Hepatic Safety of Tigecycline: Meta-Analysis (Clin Infect Dis, 2011)
[3] Prolonged Tigecycline Use: Retrospective Cohort (J Antimicrob Chemother, 2015)
[4] IDSA Guidelines: Tigecycline Monitoring
[5] Tigecycline Hepatotoxicity Review (Drug Saf, 2018)
[6] Eravacycline vs Tigecycline Trials (Lancet Infect Dis, 2019)